Predicting Amlodipine Response in Children with Hypertension
Author Information
Author(s): Wang Hui, Lin Yao, Wang Yuting, Shen Chen, Li Yaqi, Liu Yang, Shi Lin
Primary Institution: Children’s Hospital, Capital Institute of Pediatrics, Beijing, China
Hypothesis
Can plasma calcitonin gene-related peptide (CGRP) and nitric oxide (NO) predict the effectiveness of amlodipine in treating pediatric primary hypertension?
Conclusion
CGRP and NO may be valuable biomarkers for predicting amlodipine effectiveness in the treatment of pediatric primary hypertension.
Supporting Evidence
- Responders had lower CGRP and higher NO levels compared to non-responders.
- The combined model of CGRP and NO had an AUC of 0.814, indicating good predictive performance.
- The nomogram model showed good calibration and clinical applicability.
Takeaway
Doctors can use certain blood markers to tell if a medicine called amlodipine will work for kids with high blood pressure.
Methodology
The study enrolled 74 children with primary hypertension treated with amlodipine, measuring plasma CGRP and NO levels before and after treatment.
Limitations
The study is limited by its single-center design and small sample size, which may not represent the entire pediatric population.
Participant Demographics
Children and adolescents aged 6-18 years with primary hypertension.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 0.714–0.914
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website